Evidence map›Paper›PMID 28851352›Full record

ArticleJournal of biomedical science2017

Prognostic roles of pathology markers immunoexpression and clinical parameters in Hepatoblastoma.

Jia-Feng Wu, Hsiu-Hao Chang, Meng-Yao Lu, Shiann-Tarng Jou, Kai-Chi Chang, Yen-Hsuan Ni, Mei-Hwei Chang

Open access · diamondAbstract read
In one paragraph

Article in Journal of biomedical science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jia-Feng WuDepartment of Pediatrics, National Taiwan University Hospital, No. 8, Chung-Shan S. Rd, Taipei, Taiwan.
Hsiu-Hao ChangDepartment of Pediatrics, National Taiwan University Hospital, No. 8, Chung-Shan S. Rd, Taipei, Taiwan.
Meng-Yao LuDepartment of Pediatrics, National Taiwan University Hospital, No. 8, Chung-Shan S. Rd, Taipei, Taiwan.
Shiann-Tarng JouDepartment of Pediatrics, National Taiwan University Hospital, No. 8, Chung-Shan S. Rd, Taipei, Taiwan.
Kai-Chi ChangDepartment of Emergency, National Taiwan University Hospital, Taipei, Taiwan.
Yen-Hsuan NiDepartment of Pediatrics, National Taiwan University Hospital, No. 8, Chung-Shan S. Rd, Taipei, Taiwan.
Mei-Hwei ChangDepartment of Pediatrics, National Taiwan University Hospital, No. 8, Chung-Shan S. Rd, Taipei, Taiwan. changmh@ntu.edu.tw.
National Taiwan University Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatoblastoma, a leading primary hepatic malignant tumor in children, is originated from primitive hepatic stem cells. We aimed to elucidate the relationships between the histological distribution of β-catenin and hepatic stem cell markers with the clinical outcomes of hepatoblastoma.

methodsImmunohistochemistry was applied to detect β-catenin and hepatic stem cell markers expression in 31 hepatoblastoma tumors. We analyzed the relationship between the stem cell markers and the clinical course of hepatoblastoma.

resultsThirty-one hepatoblastoma patients were diagnosed at a mean age of 2.58 ± 3.78 years, and 7 (22.58%) died. A lack of anticipated decrease in alpha-fetal protein levels after neoadjuvant chemotherapy indicated a higher mortality rate. Nuclear β-catenin expression was significantly associated with membranous epithelial cell adhesion molecule (EpCAM) expression in hepatoblastoma tumor specimens. The co-expression of nuclear β-catenin and membranous EpCAM together with an age at diagnosis ≤1.25 years were predictive of an alpha-fetoprotein level < 1200 ng/mL after neoadjuvant chemotherapy (P < 0.05). An alpha-fetoprotein level < 1200 ng/mL after neoadjuvant chemotherapy and age at hepatoblastoma diagnosis ≤1.25 years are both predictors of better overall and native liver survival in hepatoblastoma patients.

conclusionsPresence of membranous EpCAM with nuclear β-catenin and younger diagnostic age of hepatoblastoma are predictive of serum alpha-fetoprotein levels drop after chemotherapy. Younger diagnostic age and lower alpha-fetoprotein levels after neoadjuvant chemotherapy and are predictive of better overall and native liver survival in hepatoblastoma patients.

Indexed as

Gene Expressionbeta CateninBiomarkers, TumorChildChild, PreschoolEpithelial Cell Adhesion MoleculeFemaleHepatoblastomaHumansInfantLiver NeoplasmsMaleNeoplastic Stem CellsPrognosisbeta CateninBiomarkers, TumorCTNNB1 protein, humanEpithelial Cell Adhesion MoleculeEpithelial cell adhesion moleculeHepatoblastomaLiver stem cellβ-catenin

Identifiers

PMID28851352
PMCPMC5574230
OpenAlexW2752887504

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.